In Q2 2025, Deerfield Management held 99 positions worth $4.4B. They initiated 16 new positions and exited 545. Their largest holding was NUVL ($1.4B). Portfolio value grew +13.7% versus the prior quarter.
Frequently asked questions
What stocks did Deerfield Management own in Q2 2025?
Deerfield Management held 99 biotech stocks in their 13F portfolio in Q2 2025. Their top positions include NUVL, OSCR, VTRS, SPRY, INDV. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
How much was Deerfield Management's portfolio worth in Q2 2025?
Deerfield Management's tracked biotech portfolio was worth $4.4B across 99 positions, with total assets under management of approximately $16B. Portfolio values are based on 13F filings with the SEC.
What did Deerfield Management buy in Q2 2025?
Deerfield Management initiated 16 new positions in Q2 2025, including LIVN, VTR, XENE, TSHA, OMDA and 11 more. They also increased 48 existing positions.
What did Deerfield Management sell in Q2 2025?
Deerfield Management fully exited 545 positions in Q2 2025, including RILYZ, WRB-PH, CGBD, WGSWW, FCN and 540 more. They also trimmed 13 existing positions.
Is Deerfield Management a biotech fund?
Multi-strategy healthcare fund with one of the longest track records in the space. Deerfield invests across public equity, private equity, structured credit, and royalties in healthcare. Known for creative financing structures and deep industry relationships across pharma and biotech.
Want AI analysis, insider signals, and catalyst overlays for Deerfield Management?
View latest Deerfield Management portfolio →